Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Adv Ther. 2022;39(1):33–43. https://doi.org/10.1007/s12325-021-01927-z.

Article  PubMed  Google Scholar 

Jha V, Al-Ghamdi SMG, Li G, Wu MS, Stafylas P, Retat L, et al. Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme. Adv Ther. 2023;40(10):4405–20. https://doi.org/10.1007/s12325-023-02608-9.

Article  PubMed  PubMed Central  Google Scholar 

Edmonston D, Lydon E, Mulder H, Chiswell K, Lampron Z, Marsolo K, et al. Concordance with screening and treatment guidelines for chronic kidney disease in type 2 diabetes. JAMA Netw Open. 2024. https://doi.org/10.1001/jamanetworkopen.2024.18808.

Article  PubMed  PubMed Central  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816.

Article  CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744.

Article  CAS  PubMed  Google Scholar 

EMPA-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27. https://doi.org/10.1056/NEJMoa2204233.

Article  Google Scholar 

Liew A, Lydia A, Matawaran BJ, Susantitaphong P, Tran HTB, Lim LL. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries—an expert consensus statement. Nephrology (Carlton). 2023;28(8):415–24. https://doi.org/10.1111/nep.14167.

Article  CAS  PubMed  Google Scholar 

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–90. https://doi.org/10.2337/dci22-0027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahtta D, Ramsey DJ, Lee MT, Chen L, Al Rifai M, Akeroyd JM, et al. Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the department of veterans affairs. Diabetes Care. 2022;45(2):372–80. https://doi.org/10.2337/dc21-1815.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arnold SV, Tang F, Cooper A, Chen H, Gomes MB, Rathmann W, et al. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocr Disord. 2022;22(1):111. https://doi.org/10.1186/s12902-022-01026-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54(7):691–708. https://doi.org/10.1007/s40262-015-0264-4.

Article  CAS  PubMed  Google Scholar 

Hu S, Lin C, Cai X, Zhu X, Lv F, Yang W, et al. Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.1018720.

Article  PubMed  PubMed Central  Google Scholar 

Shiau C-H, Tsau L-Y, Kao C-C, Peng Y-C, Bai C-H, Wu JC, et al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2023. https://doi.org/10.1007/s11255-023-03789-6.

Article  PubMed  Google Scholar 

Wang C, Zhou Y, Kong Z, Wang X, Lv W, Geng Z, et al. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(4):1018–26. https://doi.org/10.1111/dom.13620.

Article  CAS  PubMed  Google Scholar 

Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84–104. https://doi.org/10.1053/j.ajkd.2019.06.009.

Article  CAS  PubMed  Google Scholar 

Chen JY, Pan HC, Shiao CC, Chuang MH, See CY, Yeh TH, et al. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Cardiovasc Diabetol. 2023;22(1):290. https://doi.org/10.1186/s12933-023-02035-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y, Wang F-R, Wen F-F, Li C, Ye T-T. The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials. Acta Cardiol. 2023. https://doi.org/10.1080/00015385.2023.2250949.

Article  PubMed  Google Scholar 

Baigent C, Emberson J, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–801. https://doi.org/10.1016/s0140-6736(22)02074-8.

Article  CAS  Google Scholar 

Siddiqui R, Obi Y, Dossabhoy NR, Shafi T. Is there a role for SGLT2 inhibitors in patients with end-stage kidney disease? Curr Hypertens Rep. 2024;26(12):463–74. https://doi.org/10.1007/s11906-024-01314-3.

Article  PubMed  PubMed Central  Google Scholar 

Li N, Lv D, Zhu X, Wei P, Gui Y, Liu S, et al. Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis. Front Med (Lausanne). 2021;8:728089. https://doi.org/10.3389/fmed.2021.728089.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Article  PubMed  PubMed Central  Google Scholar 

Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O’Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.050391.

Article  PubMed  PubMed Central  Google Scholar 

Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B. Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease. Circulation. 2018;137(2):119–29.

Article  CAS  PubMed  Google Scholar 

Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, Khan SS, Baldridge AS, Shah SJ, Huang Y, Li C, Figtree GA, Perkovic V, Jardine MJ, Neal B, Huffman MD. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from CANAVAS program. ESC Heart Fail. 2021;8(2):1482–93. https://doi.org/10.1002/ehf2.13236.

Article  PubMed  PubMed Central  Google Scholar 

Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Cardiac and Kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-reduced trial. Circulation. 2021;143(4):310–21. https://doi.org/10.1161/CIRCULATIONAHA.120.051685.

Article  CAS  PubMed  Google Scholar 

Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, et al. Ertugliflozin and slope of chronic eGFR. Clin J Am Soc Nephrol. 2021;16(9):1345–54. https://doi.org/10.2215/cjn.01130121.

Article  CAS  PubMed  PubMed Central  Google Scholar